Key Insights

Highlights

Success Rate

91% trial completion (above average)

Published Results

142 trials with published results (23%)

Research Maturity

409 completed trials (67% of total)

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 30/100

Termination Rate

6.2%

38 terminated out of 612 trials

Success Rate

91.5%

+5.0% vs benchmark

Late-Stage Pipeline

38%

233 trials in Phase 3/4

Results Transparency

35%

142 of 409 completed with results

Key Signals

142 with results91% success38 terminated

Data Visualizations

Phase Distribution

460Total
Not Applicable (82)
Early P 1 (1)
P 1 (55)
P 2 (89)
P 3 (130)
P 4 (103)

Trial Status

Completed409
Unknown100
Terminated38
Recruiting30
Active Not Recruiting12
Withdrawn11

Trial Success Rate

91.5%

Benchmark: 86.5%

Based on 409 completed trials

Clinical Trials (612)

Showing 20 of 20 trials
NCT06786429Phase 4Not Yet RecruitingPrimary

Managing Hepatitis B (Hep. B) and Human Papilloma Virus (HPV) Related Cancers and Mental Health.

NCT00001971Recruiting

Evaluation of Patients With Liver Disease

NCT00004850Completed

Epidemiology, Infectivity and Natural History of Hepatitis C Virus Infection

NCT06422767Phase 1CompletedPrimary

Study to Evaluate the Effect of Bepirovirsen on Cardiac Conduction as Assessed by 12-lead Electrocardiogram in Healthy Volunteers

NCT05181826Recruiting

Collection of Blood From Healthy Patients, Patients With Benign Disease and Patients With Cancer

NCT06497504Phase 2Active Not RecruitingPrimary

Study of Bepirovirsen in Participants Living With Human Immunodeficiency Virus and Chronic Hepatitis B Virus Infection (B-Focus)

NCT06537414Phase 2Active Not Recruiting

A Study of Sequential Therapy With Daplusiran/Tomligisiran (DAP/TOM) Followed by Bepirovirsen in Participants Living With Chronic Hepatitis B (CHB)

NCT04954859Phase 2Active Not RecruitingPrimary

Long-term Follow-up Study to Evaluate Durability of Treatment Response in Previous Bepirovirsen Study Participants (B-Sure)

NCT06834178Recruiting

Non-interventional Study to Assess the Number of People With Untreated/Unknown HBV + HDV and HCV in South-East Austria

NCT05330455Phase 1TerminatedPrimary

Study of GSK3965193 in Healthy Participants and Participants Living With Chronic Hepatitis B Infection

NCT07637214CompletedPrimary

A Real-world Study: Analysis of the Efficacy of Antiviral Therapy in CHB Patients Over 30 Years Old, HBV DNA Positive and ALT Normal

NCT05551273Phase 2CompletedPrimary

Study of Oral TLR8 Agonist Selgantolimod on HBsAg in Participants With Both Chronic Hepatitis B and HIV

NCT03825458RecruitingPrimary

Creation of a Cohort for the Quantitation and Characterization of Circulating Viral RNAs as a New Biomarker of Hepatitis B Functional Cure.

NCT07168356Phase 1Active Not RecruitingPrimary

A Study to Evaluate Blood Levels of Bepirovirsen in Adult Participants With Severe or Moderate Kidney Disease

NCT04914611RecruitingPrimary

Real World Assessment of People Living With Chronic Hepatitis B in Australia

NCT07589985RecruitingPrimary

Hep Mec Cohort in Zambia

NCT03933384Phase 4RecruitingPrimary

Tenofovir Alafenamide Versus Entecavir for the Treatment of Chronic Hepatitis B

NCT02366286CompletedPrimary

Hepatitis B and Hepatitis C as Risk Factors for Hepatocellular Carcinoma in African and Asian Immigrants

NCT03826433Phase 1RecruitingPrimary

hUC Mesenchymal Stem Cells (19#iSCLife®-LC) in the Treatment of Decompensated Hepatitis b Cirrhosishepatitis b Cirrhosis

NCT05272735Phase 4TerminatedPrimary

HBV Vaccination of Healthy Volunteers to Evaluate the Composition of Germinal Centers

Scroll to load more

Research Network

Activity Timeline